Further Information
IKBB, TRIP9, HNF4, NR2A1, TCF14, I-kappa-B-beta, IKB-B, IKBB, NF-kappa-BIB, NF-kappaB inhibitor beta
Immunohistochemistry: 1:50~1:100
Inhibits NF-κ-B by complexing with and trapping it in the cytoplasm. However, the unphosphorylated form resynthesized after cell stimulation is able to bind NF-κ-B allowing its transport to the nucleus and protecting it to further IKBA-dependent inactivation. Association with inhibitor kappa B-interacting NKIRAS1 and NKIRAS2 prevent its phosphorylation rendering it more resistant to degradation, explaining its slower degradation.
- Shirane, M. et al. (1999) J Biol Chem 274, 28169-28174. DiDonato J, et al. (1996) Mol Cell Biol 16 (4): 1295-304
Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
1 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
IkB-beta (Phospho-Ser23) antibody was raised against a peptide sequence around phosphorylation site of serine 23 (L-G-S (p) -L-G) derived from Human IkappaB-β.
Phospho-Specific
4793
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta
NFKBIB
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
48 kDa
NP_001001716.1
48928017
Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
Phospho-Specific,Apoptosis,Cancer
This antibody detects endogenous level of IkappaB-β only when phosphorylated at serine 23.
Q15653
